<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026674</url>
  </required_header>
  <id_info>
    <org_study_id>FLO-ISR-01</org_study_id>
    <nct_id>NCT02026674</nct_id>
  </id_info>
  <brief_title>Reliability of Home Uroflowmetery Using a Disposable Digital Device</brief_title>
  <official_title>Reliability of Home Uroflowmetery Using a Disposable Digital Device in Comparison to Standard Clinical Uroflowmetry in Men With LUTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flometrica Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flometrica Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FloRite™ device is a disposable urine flow meter, indicated for use in a home setting.&#xD;
&#xD;
      The device provides Urofowmetry measurements, similar to clinic's measurements. Clinic-based&#xD;
      uroflowmetry has some flaws; the setting is artificial and often it is difficult to void at&#xD;
      the desired moment. Moreover, a single measurement of the voided parameters is a poor&#xD;
      representative of the patient condition due to high variability of the measured parameters.&#xD;
      Performing multiple Urofowmetry measurements provides representative and more accurate&#xD;
      results, in a more patient-friendly, cost effective method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FloRite™ product is a disposable urine flow meter. The patient needs to urinate into the&#xD;
      device and at the end of urination the patient needs to disconnect a USB drive from the&#xD;
      device, dispose the device's container and keep the USB drive that contains the test data.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      • Usability evaluation of the FloRite™ system with LUTS patients.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Comparison of uroflowmetric parameters obtained using home disposable digital&#xD;
           uroflowmetry device with standard clinic-based uroflowmetry.&#xD;
&#xD;
        -  Evaluation of diurnal variations in uroflowmetric parameters obtained using home&#xD;
           uroflowmetry&#xD;
&#xD;
      Primary outcome measures&#xD;
&#xD;
      • Successful use of FloRite™ system in LUTS patients, defined as:&#xD;
&#xD;
        -  Successful unpacking and installation&#xD;
&#xD;
        -  Successful understanding of the user manual&#xD;
&#xD;
        -  Ability of the patients to operate the device as define by a successful test completion&#xD;
           and data transmission&#xD;
&#xD;
        -  Successful retrieval of the DOK&#xD;
&#xD;
        -  Absence of:&#xD;
&#xD;
        -  Device dropping down&#xD;
&#xD;
        -  Urination outside the container&#xD;
&#xD;
        -  Urination on the electronic unit&#xD;
&#xD;
      Secondary outcome measures:&#xD;
&#xD;
      • Comparison of uroflowmetric parameters as measured by&#xD;
&#xD;
      FloRite™ system and standard clinical uroflowmetry as defined by [Time Frame: Days 0, 1, 6&#xD;
      and 7]:&#xD;
&#xD;
        -  Qmax - Max Flow Rate&#xD;
&#xD;
           • Evaluation of diurnal variations in uroflowmetric parameters obtained using home&#xD;
           uroflowmetry as defined by [Time Frame: Days 1, 6]:&#xD;
&#xD;
        -  Urine flow graph&#xD;
&#xD;
        -  Tdelay - Delay time&#xD;
&#xD;
        -  T100 - Voiding Time&#xD;
&#xD;
        -  TQ - Flow Time&#xD;
&#xD;
        -  Tqmax - Time to max Flow&#xD;
&#xD;
        -  Qmax - Max Flow Rate&#xD;
&#xD;
        -  Qave - Average Flow Rate&#xD;
&#xD;
        -  Vcomp - Voided Volume Up to 30 completed patients&#xD;
&#xD;
      Inclusion criteria&#xD;
&#xD;
        -  LUTS patients&#xD;
&#xD;
        -  Male 18&lt;Age &lt;65&#xD;
&#xD;
        -  Ability to speak, read and understand instructions&#xD;
&#xD;
        -  Patient willing to sign an Informed Consent Exclusion criteria&#xD;
&#xD;
        -  Mentally disabled patients&#xD;
&#xD;
        -  Infectious diseases&#xD;
&#xD;
        -  Catheterized patients&#xD;
&#xD;
        -  Buried penis due to obesity The patients will be consented if found eligible.&#xD;
           Prospective, self- controlled, interventional, clinical study&#xD;
&#xD;
      On the baseline visit, after eligibility is confirmed and after consenting the patients, the&#xD;
      following steps will be taken:&#xD;
&#xD;
        -  Standard clinical uroflowmetry&#xD;
&#xD;
        -  Training how to use the system&#xD;
&#xD;
        -  Unpacking and setting up the device (supervised by an observer)&#xD;
&#xD;
      The following day, the patient will perform home test with the FloRite™ system. Similar test&#xD;
      will be conducted on Day 6 of the study.&#xD;
&#xD;
      The test results will be transferred either by e- mailing the data stored on the DOK or by&#xD;
      bringing the DOK itself to the clinic on the 7th day.&#xD;
&#xD;
      On Day 7 of the study, the patients will be asked to return to the clinic for standard&#xD;
      clinical uroflowmetry. In addition, the patient will fill a satisfaction questionnaire.&#xD;
&#xD;
      All the measurements must be standard and performed at around the same time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usability evaluation of the FloRite™ system with LUTS patients.</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Primary outcome measures&#xD;
• Successful use of FloRite™ system in LUTS patients, defined as:&#xD;
Successful unpacking and installation&#xD;
Successful understanding of the user manual&#xD;
Ability of the patients to operate the device as define by a successful test completion and data transmission&#xD;
Successful retrieval of the DOK&#xD;
Absence of:&#xD;
Device dropping down&#xD;
Urination outside the container&#xD;
Urination on the electronic unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Qmax (Max Flow Rate)</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of Qmax as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tdelay</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of Tdelay as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of uroflowmetric parameter: T100 - Voiding Time</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of T100 as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of uroflowmetric parameters of TQ - Flow Time</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of TQ - Flow Time as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of uroflowmetric parameters of Tqmax - Time to max Flow</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of Tqmax - Time to max Flow as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of uroflowmetric parameters of Qave</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of Qave as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of uroflowmetric parameters of Vcomp - Voided volume</measure>
    <time_frame>Dec-2014</time_frame>
    <description>Comparison of uroflowmetric parameters of Vcomp - Voided volume as measured by FloRite™ system and standard clinical uroflowmetry [Time Frame: Days 0, 1, 6 and 7].</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>FloRite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUTS patients that used FloRite for home urine flow diagnostics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FloRite</intervention_name>
    <description>Disposable home use urine flow meter.</description>
    <arm_group_label>FloRite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LUTS patients&#xD;
&#xD;
          -  Male 18&lt;Age &lt;65&#xD;
&#xD;
          -  Ability to speak, read and understand instructions&#xD;
&#xD;
          -  Patient willing to sign an Informed Consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Mentally disabled patients&#xD;
&#xD;
          -  Infectious diseases&#xD;
&#xD;
          -  Catheterized patients&#xD;
&#xD;
          -  Buried penis due to obesity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilan Leibovitch, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeev Cohen, M.Sc.</last_name>
    <phone>+972-52-4471297</phone>
    <email>zeev@flometrica.cm</email>
  </overall_contact>
  <location>
    <facility>
      <name>&quot;Meir&quot; Hospital</name>
      <address>
        <city>Kfar-Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilan Leibovitch, Prof.</last_name>
      <phone>+972-9-747-1557</phone>
      <email>Leibovitchi@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Ilan Leibovitch, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.flometrica.com</url>
    <description>Sponsor web site.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>December 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urineflow</keyword>
  <keyword>luts</keyword>
  <keyword>urine flow</keyword>
  <keyword>uroflometry</keyword>
  <keyword>bph</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

